Abbott (NYSE: ABT) has announced the in-licensing of several biosimilar drugs from Spain-based biotechnology firm mAbxience for select markets in Latin America, Southeast Asia, the Middle East, and Africa. mAbxience, which had its majority stake acquired by German group Fresenius (ETR: FRE) from Argentina-based Insud Pharma last year, specializes in biosimilars covering oncology, women’s health, and respiratory diseases.
Details of the Agreement and Product Pipeline
The products in question include biosimilars that are currently in clinical development or under regulatory review, with some expected to be ready for launch by 2025. mAbxience will be responsible for manufacturing the biologics at its facilities in Argentina and Spain, building on its existing capabilities.
Historical Collaboration and Portfolio
This collaboration between Abbott and mAbxience follows an initial partnership in 2018 that saw the licensing of two biosimilars for markets in Chile, Central America, Colombia, and Peru. According to Fineline Info & Tech data, mAbxience’s portfolio includes biosimilars of rituximab and bevacizumab, which are significant molecules in the fields of oncology and other therapeutic areas.-Fineline Info & Tech
